Comparing probabilistic and descriptive analyses of time-dose-toxicity relationship for determining no-observed-adverse-effect level in drug development.

[1]  Chao Chen.  Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil , 2013, European Journal of Clinical Pharmacology.

[2]  A. Berges,et al.  Dose finding by concentration-response versus dose-response: a simulation-based comparison , 2013, European Journal of Clinical Pharmacology.

[3]  Daniel Gerhard,et al.  A Unified Framework for Benchmark Dose Estimation Applied to Mixed Models and Model Averaging , 2013 .

[4]  B. Hamrén,et al.  Longitudinal Model‐Based Meta‐Analysis in Rheumatoid Arthritis: An Application Toward Model‐Based Drug Development , 2012, Clinical pharmacology and therapeutics.

[5]  D R Mould,et al.  Model‐Based Meta‐Analysis: An Important Tool for Making Quantitative Decisions During Drug Development , 2012, Clinical pharmacology and therapeutics.

[6]  David H. Salinger,et al.  A dose–response Meta‐Analysis for Quantifying Relative Efficacy of Biologics in Rheumatoid Arthritis , 2011, Clinical pharmacology and therapeutics.

[7]  T. Michele,et al.  The safety of tiotropium--the FDA's conclusions. , 2010, The New England journal of medicine.

[8]  D. Howells,et al.  Can Animal Models of Disease Reliably Inform Human Studies? , 2010, PLoS medicine.

[9]  Matthew W Wheeler,et al.  Benchmark Dose Estimation Incorporating Multiple Data Sources , 2009, Risk analysis : an official publication of the Society for Risk Analysis.

[10]  N. Shanks,et al.  Are animal models predictive for humans? , 2009, Philosophy, ethics, and humanities in medicine : PEHM.

[11]  M O Karlsson,et al.  Diagnosing Model Diagnostics , 2007, Clinical pharmacology and therapeutics.

[12]  Ralph L Kodell,et al.  A probabilistic framework for non-cancer risk assessment. , 2007, Regulatory toxicology and pharmacology : RTP.

[13]  Jeffery A Engelhardt,et al.  The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s). , 2005, Regulatory toxicology and pharmacology : RTP.

[14]  Wout Slob,et al.  A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  Salomon Sand,et al.  The Benchmark Dose Method—Review of Available Models, and Recommendations for Application in Health Risk Assessment , 2003, Critical reviews in toxicology.

[16]  Salomon Sand,et al.  Evaluation of the benchmark dose method for dichotomous data: model dependence and model selection. , 2002, Regulatory toxicology and pharmacology : RTP.

[17]  M. Pieters,et al.  A Probabilistic Approach for Deriving Acceptable Human Intake Limits and Human Health Risks from Toxicological Studies: General Framework , 1998, Risk analysis : an official publication of the Society for Risk Analysis.

[18]  W Leisenring,et al.  Statistical properties of the NOAEL. , 1992, Regulatory toxicology and pharmacology : RTP.

[19]  Crump Ks,et al.  An improved procedure for low-dose carcinogenic risk assessment from animal data. , 1984 .